This pilot phase IIb trial studies how well pembrolizumab and CXCR4 antagonist BL-8040 work
in treating patients with pancreatic cancer that has spread to other places. Immunotherapy
with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. CXCR4
antagonist BL-8040 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Giving pembrolizumab and CXCR4 antagonist BL-8040 may work better in
treating patients with pancreatic cancer.